Expanding our universe
Not sure who first coined the term Diabesity (Diabetes + Obesity) but it’s more appropriate than ever. The biggest news from ADA came on Monday when Lilly released results for their next gen obesity candidate Retatrutide. Even before that Lilly made news with their oral version of Trulicity. Not to be out done Novo Nordisk made news with their expanding obesity pipeline along with their once-weekly insulin.
Dexcom and Abbott have joined the obesity arms race repositioning the Libre and G7 as effective weight loss tools.
The impact of this obesity arms race is amazing as several of the . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.